753 related articles for article (PubMed ID: 28799305)
1. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
3. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
[TBL] [Abstract][Full Text] [Related]
4. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of rifaximin in management of hepatic encephalopathy.
Wahib AA; El-Deen Salem MN; Ahmed MA; El-Dessouky YM; El-Tiby DM; El-Mola K; El-Sayed AM
J Egypt Soc Parasitol; 2014 Dec; 44(3):677-85. PubMed ID: 25643509
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy for the treatment and prevention of hepatic encephalopathy.
Mohammad RA; Regal RE; Alaniz C
Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
[TBL] [Abstract][Full Text] [Related]
8. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO; Eaton-Maxwell A
Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
[TBL] [Abstract][Full Text] [Related]
12. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
13. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
Leevy CB; Phillips JA
Dig Dis Sci; 2007 Mar; 52(3):737-41. PubMed ID: 17245628
[TBL] [Abstract][Full Text] [Related]
14. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
15. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
16. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
Hudson M; Schuchmann M
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy.
Sharma BC; Singh J; Srivastava S; Sangam A; Mantri AK; Trehanpati N; Sarin SK
J Gastroenterol Hepatol; 2017 Jun; 32(6):1234-1239. PubMed ID: 27885712
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin for the treatment of hepatic encephalopathy.
Mantry PS; Munsaf S
Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
[TBL] [Abstract][Full Text] [Related]
19. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
